In diabetic kidney disease (DKD), targeting TRAIL/DR5 signaling can inhibit podocyte PANoptosis, with soluble DR5-Fc showing therapeutic effects in animal models (33). This evidence concerns the gene TNFRSF10B and diabetic kidney disease.